Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...

Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Chardan Capital reissued their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $65.00 price ...

Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy ...

While data on functional endpoints are still to come, Avidity Biosciences Inc. executives said the firm is moving ahead with ...

Analysts have recently evaluated Avidity Biosciences and provided 12-month price targets. The average target is $69.0, accompanied by a high estimate of $72.00 and a low estimate of $65.00. This ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment ...